Europe Heart Valve Devices Market Report and Forecast 2025-2034

The Europe heart valve devices market was valued at USD 3.69 Billion in 2024, driven by the rising prevalence of cardiovascular diseases and increased funding for minimally invasive valve therapies across the region. The market is anticipated to grow at a CAGR of 9.50% during the forecast period of 2025-2034, with the values likely to reach USD 9.14 Billion by 2034. Technological advancements in transcatheter valve replacement and repair systems, are improving outcomes and expanding the eligible patient pool. Moreover, increased clinical adoption of TAVI (transcatheter aortic valve implantation), particularly for high-risk and inoperable patients are aiding growth in the market value.

Europe Heart Valve Devices Market Overview

Heart valve devices are medical implants designed to repair or replace damaged heart valves, ensuring proper blood flow direction and preventing complications such as valve stenosis or regurgitation. The market for heart valve devices in Europe is expanding due to the rising prevalence of cardiovascular diseases, an increasing aging population, advancements in transcatheter technologies, and growing preference for minimally invasive surgical procedures. It is anticipated to grow at a CAGR of 9.50% during the forecast period of 2025-2034.

Europe Heart Valve Devices Market Growth Drivers

Rising Cardiovascular Disease Burden to Drive the Market Expansion

The increasing prevalence of cardiovascular disease (CVD) remains a key growth driver in the heart valve devices market in Europe. As reported by the World Heart Federation, CVD is the leading cause of death in the European Union, impacting over 60 million people and resulting in more than 1.7 million deaths annually. This rising prevalence continues to propel demand for advanced heart valve interventions, supporting sustained market growth across the region.

Europe Heart Valve Devices Market Trends

Some of the notable trends include rising funding for minimally invasive therapies:

Increased Funding for Minimally Invasive Valve Therapies is Likely to Boost Market Growth

A notable trend in the European market for heart valve devices is the surge in investments, supporting innovative valve treatment technologies. For instance, in August 2024, CroíValve, a European Institute of Innovation and Technology-backed medtech start-up, raised USD 16 million in Series B funding to advance its heart valve treatment technology, DUO for treating tricuspid regurgitation. This funding momentum is expected to accelerate market growth and technological advancement.

Europe Heart Valve Devices Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Valve Type

• Biological (Tissue) Valve
• Mechanical Valve

Market Breakup by Product Type

• Replacement Devices
• Mechanical Valve
• Bioprosthetic Valve
• Transcatheter Aortic Valve Replacement (TAVR)
• Repair Devices
• Surgical Valve
• Transcatheter Mitral Valve Replacement (TMVR)
• Balloon Valvuloplasty Devices

Market Breakup by Procedure

• Open Surgery
• Minimally Invasive Surgery (MIS)

Market Breakup by End User

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Others

Market Breakup by Region

• United Kingdom
• Germany
• France
• Italy
• Others

Europe Heart Valve Devices Market Share

Biological Valves are Expected to Lead the Valve Type Segment

Based on valve types, the market is divided into biological (tissue) valves and mechanical valves. Biological valves will likely to dominate the segment due to their enhanced safety profile, reduced need for lifelong anticoagulation, and growing adoption among elderly patients. Together, these factors are driving the increasing preference for tissue-based valves across surgical and transcatheter procedures.

Segmentation by Product Type to Witness Growth in the Market

Based on the product type, the market is segmented into replacement devices (mechanical valve, bioprosthetic valve, transcatheter aortic valve replacement) and repair devices (surgical valve, transcatheter mitral valve replacement, balloon valvuloplasty devices). Replacement devices are expected to witness substantial growth, primarily due to the rapid adoption of TAVR and rising prevalence of aortic valve disorders.

Minimally Invasive Surgeries to Dominate Procedure Segment

The market share by procedure includes open surgeries and minimally invasive surgeries (MIS). Minimally invasive surgery is projected to lead the segment, supported by technological advancements, faster recovery times, reduced complications, and increasing patient demand. Together, these advantages contribute to its expanding adoption in both replacement and repair interventions.

Hospitals to Lead the End User Segmentation in the Europe Heart Valve Devices Market

Hospitals, ambulatory surgical centers (ASCs), and others together make up the end-user segmentation. Hospitals are expected to hold the largest share due to their comprehensive care capabilities, access to advanced technologies, and availability of specialized cardiac teams. Together, these factors ensure hospitals remain the primary centers for heart valve procedures.

Europe Heart Valve Devices Market Analysis by Region

The market is divided into regions such as the United Kingdom, Germany, France, Italy, and others. The United Kingdom is likely to dominate the market, driven by advanced healthcare infrastructure, rising cardiovascular disease incidence, and increasing adoption of transcatheter procedures. Germany holds a significant share due to its strong medical technology sector, while the France benefit from government support and growing demand for minimally invasive treatments.

Leading Players in the Europe Heart Valve Devices Market

The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Medtronic plc

Medtronic plc, established in 1949 and headquartered in the United States, is a global leader in healthcare technology with a strong presence in the European heart valve devices market. In October 2024, the company launched the Avalus Ultra Bioprosthesis valve in Western Europe. This next-generation surgical aortic valve, designed for enhanced durability and ease of implantation, builds on a decade of clinical success with the Avalus valve. Medtronic’s expanding cardiac surgery portfolio highlights its commitment to advancing cardiovascular care across the region.

Edwards Lifesciences Corporation

Headquartered in Irvine, California, and established in 1958, Edwards Lifesciences Corporation is a leading innovator in structural heart therapies. In May 2024, the company expanded its presence in the Europe heart valve devices market by launching the Sapien 3 Ultra Resilia valve, a transcatheter aortic valve featuring Resilia tissue technology that enhances durability and reduces calcification. With CE Mark approval, this advanced device addresses native aortic stenosis and failed bioprosthetic valves across all surgical risk levels. Edwards' strategic focus on innovation and patient-centric care reinforces its strong market position and supports growing demand for minimally invasive valve replacement options in Europe.

Abbott

Abbott is a leader in innovative healthcare solutions, including cardiovascular devices. It is headquartered in Illinois, United States and was established in 1888. Abbott's TriClip transcatheter edge-to-edge repair (TEER) system, approved by the FDA in April 2024, is designed for treating tricuspid regurgitation. This minimally invasive device has shown positive results in improving patients' quality of life and reducing symptoms. Abbott's commitment to advancing structural heart therapies, including the MitraClip and Navitor systems, reinforces its strong position in the European heart valve devices market.

Boston Scientific Corporation

Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific Corporation is a leading global medical technology company. In August 2024, it received CE mark approval for its Acurate Prime aortic valve system, an advanced transcatheter aortic valve replacement (TAVR) device designed for patients with severe aortic stenosis. This next-generation valve expands treatment options for larger anatomies and enhances procedural accuracy through a redesigned deployment system.

Other key players in the market include Corcym Group, B. Braun SE, Getinge AB, Shockwave Medical Inc. (Johnson & Johnson, Services Inc.), JenaValve Technology, Inc., and Xeltis.

Key Questions Answered in the Europe Heart Valve Devices Market Report

• What was the Europe heart valve devices market value in 2024?
• What is the Europe heart valve devices market forecast outlook for 2025-2034?
• What is the market segmentation based on valve type?
• What is the market breakup based on the product type?
• How is the market segmented based on procedure?
• How is the market divided based on the end user?
• What major factors aid the Europe heart valve devices market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major Europe Heart Valve Devices market trends?
• Which valve type is expected to dominate the market segment?
• Which product type is projected to lead the market segment?
• Which procedure is anticipated to drive the market segment?
• Which end user is likely to dominate the market segment?
• Who are the key players in the Europe heart valve devices market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.